A promising approach to increase the diagnostic accuracy for dementia diagnosis is the use of biochemical markers (biomarkers) that are present in easily accessible body fluids like serum, plasma or cerebrospinal fluid (CSF).
Within the Reference Center for Biological Markers of Memory Disorders, we contribute to the development and characterization of biomarkers, meanwhile developing and validating biomarkers-based diagnostic models that can easily be applied in routine clinical diagnosis.
Indeed, several studies have confirmed the relevance of total tau-protein (T-tau) and β-amyloid peptide (Aβ1-42) in the pathogenic processes associated with dementias of neurodegenerative origin.
The combined assessment of CSF A β42, T-tau, and tau phosphorylated at threonine 181 (P-tau181P) levels is routinely performed by means of commercially available ELISA kits and was demonstrated to have added diagnostic value for AD diagnosis and to increase specificity for discriminating AD from other (degenerative) dementias. Should you wish to send future CSF samples for biomarker analyses, please fill out the request form. It is moreover important to pay attention to the following guidelines in order to ensure reliable biomarker results (see as well Technical directions and forms):
- Please sample CSF in polypropylene vials
- Minimal sample volume: 2 ml
- CSF samples that are macroscopically hemorrhagic, should be excluded
- Avoid freeze-thaw cycles:
- In case the samples are shipped at room temperature, it should arrive at the lab within 24 hours
- In case the samples are frozen, they should be shipped on dry ice
Please inform your patients that the cost price for these analyses is €165, which is not covered by the regular Belgian insurance companies (refunding is however provided by some supplementary hospitalization insurances).
Read our latest newsletter (September 2019)